GT Medical Technologies has completed the acquisition of Perspective Therapeutics subsidiary Isoray Medical's cesium-131 assets.
The purchase makes GT Medical the sole manufacturer of cesium-131 brachytherapy seeds for cancer treatments, and is part of its plan to expand adoption of its GammaTile therapy in the U.S., it said. It was initiated in December of last year. GT Medical will retain use of Isoray's cesium-131 manufacturing facility in Richland, WA.
